Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guard-06
ChiCTR2400080573Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology & Oncology, Harbin First Hospital
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of efbemalenograstim alfa in neutropenia and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Institute of Hematology & Oncology, Harbin First Hospital. Primary endpoint: Incidence of grade ≥ 3 neutropenia after chemotherapy cycle 1. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenianon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR2400080573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080573.